<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553316</url>
  </required_header>
  <id_info>
    <org_study_id>PK101_P101</org_study_id>
    <nct_id>NCT03553316</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Between PK101-001 and PK101-002</brief_title>
  <official_title>A Randomized, Open Labeled, Multiple Dose, 2-Sequence, 2-Period Cross-over Phase 1 Study to Evaluate the Drug-Drug Interaction of PK101-001 and PK101-002 in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PMG Pharm Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PMG Pharm Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the drug-drug interaction of PK101-001 and PK101-002 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Actual">April 24, 2019</completion_date>
  <primary_completion_date type="Actual">March 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 hour</time_frame>
    <description>Area under the plasma drug concentration-time curve for PK101-002 at Steady-state (between dose times)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 hour</time_frame>
    <description>The maximum (or peak) serum concentration for PK101-002 at Steady-state</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Sequence (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Subject: 24
Wash out Period: over 7 days (between each period)
Investigators Products(IPs) for Period1: A (Single)= PK101-002
IPs for Period2: B (Combination)= PK101-001, PK101-002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence (2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Subject: 24
Wash out Period: over 7 days (between each period)
IPs for Period1: B (Combination)= PK101-001, PK101-002
IPs for Period2: A (Single)= PK101-002</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PK101-002</intervention_name>
    <description>-(Single) PK101-002</description>
    <arm_group_label>Sequence (1)</arm_group_label>
    <arm_group_label>Sequence (2)</arm_group_label>
    <other_name>A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PK101</intervention_name>
    <description>-(Combination) PK101-001, PK101-002</description>
    <arm_group_label>Sequence (1)</arm_group_label>
    <arm_group_label>Sequence (2)</arm_group_label>
    <other_name>B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults ≥ 19 years of age (on the day of screening)

          -  No congenital or chronic diseases and no abnormal signs determined by medical
             examinations

          -  Not abnormal or not clinical significant lab values

          -  90mmHg ≤ (SBP) ≤ 139mmHg, 60mmHg ≤ (DBP) ≤ 89mmHg

          -  18Kg/(m)^2 ≤ (BMI) ≤30Kg/(m)^2

        Exclusion Criteria:

          -  Subjects who were administered below medications within 30 days (barbiturates, drugs
             of induced or suppressive drug metabolizing enzyme, etc)

          -  Subjects who were administered medications of prohibition within 10 days

          -  Heavy drinking within 30 days (female: over 14units/week, male:over 21units/week)

          -  Heavy smoker within 30 days (over 20 cigarettes per day)

          -  Subjects who previously participated in other clinical trials or bioequivalence Test
             within 90 days

          -  Subjects who donated whole blood within 60 days or donated component blood within 14
             days or received blood transfusion within 30 days

          -  Subjects who have hypersensitivity for investigational products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Hyun Kang</last_name>
    <role>Principal Investigator</role>
    <affiliation>H Plus Yangji Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H Plus Yangji Clinical Research Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 27, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

